Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| GOSS | 8-K | bearish | 6/10 | Gossamer Bio effected a 1-for-80 reverse stock split and reduced authorized shares from 4 billion to 50 million to regai | Sep 11, 2026 |
| TPST | PRESS-RELEASE | bearish | 6/10 | Tempest Therapeutics announced a private placement of ~3.1M shares and warrants at $0.805/unit, raising ~$2.5M in gross | Sep 11, 2026 |
| ALLR | PRESS-RELEASE | neutral | 4/10 | Allarity Therapeutics announced that its newly formed SPAC subsidiary, Allarity Acquisition Corp., filed an S-1 registra | Sep 11, 2026 |
| TCRX | 8-K | neutral | 5/10 | TScan Therapeutics filed an 8-K on September 11, 2026, disclosing a retention program approved by the Compensation Commi | Sep 11, 2026 |
| MDCX | 8-K | bearish | 6/10 | Medicus Pharma issued 8,529,412 restricted common shares to officers and employees in lieu of $1.45 million in cash bonu | Sep 11, 2026 |
| RLMD | CLUSTER | bullish | 6/10 | RLMD CEO Sergio Traversa and CFO Maged Shenouda collectively purchased $1.67M of stock in open-market transactions over | Sep 11, 2026 |
| IRD | 8-K | bullish | 7/10 | Opus Genetics filed an 8-K correcting an immaterial error in the translation of logMAR visual acuity into ETDRS letters | Sep 11, 2026 |
| RADX | 6-K | neutral | 4/10 | Radiopharm Theranostics reported that all 14 resolutions at its September 11, 2026 General Meeting were carried by poll, | Sep 11, 2026 |
| ELAN | PRESS-RELEASE | neutral | 1/10 | Elanco Animal Health announced it will host a conference call on November 6, 2026 to discuss its Q3 2026 results. | Sep 11, 2026 |
| KPTI | 8-K | bearish | 9/10 | Karyopharm Therapeutics has entered into a forbearance agreement with 100% of its term loan lenders, convertible notehol | Sep 11, 2026 |
| EXEL | 8-K | bearish | 6/10 | Exelixis disclosed that the FDA extended the review period for its NDA for zanzalintinib (in combination with atezolizum | Sep 11, 2026 |
| GHRS | 6-K | neutral | 2/10 | GH Research PLC filed a 6-K announcing it will hold one-on-one investor meetings during the Morgan Stanley 24th Annual G | Sep 11, 2026 |
| LPCN | 8-K | neutral | 2/10 | Lipocine Inc. filed an 8-K to disclose a modification to its existing Sales Agreement with A.G.P./Alliance Global Partne | Sep 11, 2026 |
| BBOT | EFFECT | bearish | 5/10 | BridgeBio Oncology Therapeutics, Inc. (BBOT) filed an EFFECT notice on September 10, 2026, indicating that its S-3 shelf | Sep 11, 2026 |
| BETRF | 6-K | neutral | 4/10 | BetterLife Pharma appointed Charles Duncan, PhD as Director and Chair of the Audit Committee, granted him 625,000 stock | Sep 11, 2026 |
| SPRO | EFFECT | bearish | 7/10 | The SEC declared effective Spero Therapeutics' S-3 shelf registration (File No. 333-298641) on September 10, 2026, enabl | Sep 11, 2026 |
| VNRX | EFFECT | bearish | 7/10 | VolitionRx's S-3 shelf registration (File No. 333-298627) became effective on September 9, 2026, immediately enabling th | Sep 11, 2026 |
| CRDL | 6-K | neutral | 2/10 | Cardiol Therapeutics filed a Form 6-K on September 10, 2026, disclosing several historical agreements as exhibits: a 201 | Sep 11, 2026 |
| CATX | PRESS-RELEASE | neutral | 3/10 | Perspective Therapeutics announced that updated data on its [212Pb]VMT-α-NET program for neuroendocrine tumors (NETs) ha | Sep 11, 2026 |
| GRCE | CLUSTER | bullish | 6/10 | Two insiders at Grace Therapeutics, including the CEO and a 10% owner, made open-market purchases totaling $226K in a 7- | Sep 11, 2026 |
| JAZZ | CLUSTER | neutral | 2/10 | A small insider selling cluster at Jazz Pharmaceuticals, with the CEO and a director selling a combined ~$2M in open-mar | Sep 11, 2026 |
| UTHR | CLUSTER | mixed | 4/10 | CEO Martine Rothblatt sold ~$5.9M of UTHR stock over two days (Sep 8-9), including shares acquired via option exercises | Sep 11, 2026 |
| JNJ | COURT-RULING | neutral | 1/10 | A district court dismissed a product liability complaint against Johnson & Johnson without prejudice, granting leave to | Sep 10, 2026 |
| INBX | CLUSTER | bullish | 7/10 | CEO Mark Lappe made a large open-market purchase cluster totaling ~$2.6M across six trades on September 8, 2026, alongsi | Sep 10, 2026 |
| CYCN | 3 | neutral | 3/10 | CEO Jonathan Violin and director Heidi Henson filed initial beneficial ownership statements (Form 3) following the Septe | Sep 10, 2026 |
| IPSC | 3 | neutral | 2/10 | Joseph Truitt filed a Form 3 initial statement of beneficial ownership with Century Therapeutics, Inc. (IPSC), along wit | Sep 10, 2026 |
| RXRX | CLUSTER | neutral | 2/10 | CEO Najat Khan and Director Blake Borgeson sold a combined $179K in open-market RXRX shares over a one-week window. The | Sep 10, 2026 |
| CRDL | 6-K | neutral | 4/10 | Cardiol Therapeutics filed a preliminary base shelf prospectus for up to US$150 million, enabling future offerings of co | Sep 10, 2026 |
| SNTI | S-3/A | bearish | 8/10 | Senti Biosciences filed an S-3/A to register 25,555,024 shares of common stock for resale by selling securityholders (Ce | Sep 10, 2026 |
| WHWK | 8-K | neutral | 3/10 | Whitehawk Therapeutics appointed Vijay Iyengar, M.D., a former Incyte executive, to its board of directors, filling a ne | Sep 10, 2026 |